Weekly Digest – January 2025 Weekly Digest – January 2025 16 Jan 2025: Innovent receives NMPA Breakthrough Therapy Designation for IBI343 (anti-CLDN18.2 ADC) as monotherapy for advanced Pancreatic Cancer Innovent Biologics received Breakthrough Therapy Designation (BTD) from the NMPA for […]
Weekly Digest – January 2025 Weekly Digest – January 2025 13 Jan 2025: Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated Non-Small Cell Lung Cancer Datopotamab deruxtecan (Dato-DXd) received FDA Priority Review for […]
Weekly Digest – January 2025 Weekly Digest – January 2025 10 Jan 2025: Mersana Therapeutics announces additional FDA Fast Track Designation granted to Emiltatug Ledadotin (XMT-1660) XMT-1660 (Emi-Le) received a new Fast Track designation for advanced or metastatic HER2-low or HER2-negative […]
Weekly Digest – January 2025 Weekly Digest – January 2025 15 Jan 2025: Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference Celltrion unveiled its strategic roadmap for innovative drug development, […]
Weekly Digest – January 2025 Weekly Digest – January 2025 15 Jan 2025: Zai Lab announces positive topline results for TIVDAK in the China subpopulation of the global phase 3 innovaTV 301 trial in patients with recurrent or metastatic Cervical […]
Weekly Digest – January 2025 Weekly Digest – January 2025 13 Jan 2025: Elevation Oncology provides updates on differentiated ADC programs and upcoming milestones Elevation Oncology initiated dosing in a Phase 1 clinical trial evaluating EO-3021, a Claudin 18.2 ADC, […]
Weekly Digest – January 2025 Weekly Digest – January 2025 13 Jan 2025: Daiichi Sankyo acquires Intellectual Property Rights for anti-TAMUC1 antibody in DS-3939 from Glycotope Daiichi Sankyo has agreed to pay $132.5 million to Glycotope to acquire the intellectual […]
